The critical role of adenosine A2A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases

Microbes and Infection

Volumn 5, Issue 6, 2003, Pages 515-526

  Thiel, Manfred ^a,b   Caldwell, Charles C ^a   Sitkovsky, Michail V ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Adenosine; Infectious disease; Receptor; Sepsis

Indexed keywords

2 CHLOROADENOSINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2',5' DIDEOXYADENOSINE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE DERIVATIVE; ADENOSINE KINASE INHIBITOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; AZATHIOPRINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; GP 515; KF 24345; KT 5720; MDL 201112; METHOTREXATE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PENTOSTATIN; PENTOXIFYLLINE; PROSTAGLANDIN; ROLIPRAM; SALMETEROL; UNCLASSIFIED DRUG; WRC 0407; ZYMOSAN;

B LYMPHOCYTE; CARDIOVASCULAR DISEASE; CELL ACTIVITY; CELL FUNCTION; CELL TYPE; DENDRITIC CELL; DOWN REGULATION; HOMEOSTASIS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOCOMPETENT CELL; INFECTION; INFECTION RISK; INFLAMMATION; MONONUCLEAR PHAGOCYTE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; T LYMPHOCYTE; THYMOCYTE;

EID: 0038706369     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(03)00068-6     Document Type: Review

References (99)

1. Bone R.C., Balk R.A., Cerra F.B., Dellinger R.P., Fein A.M., Knaus W.A., Schein R.M., Sibbald W.J. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 101:1992;1644-1655.
2. Sala-Newby G.B., Skladanowski A.C., Newby A.C. The mechanism of adenosine formation in cells. Cloning of cytosolic 5'-nucleotidase-I. J. Biol. Chem. 274:1999;17789-17793.
3. Decking U.K., Schlieper G., Kroll K., Schrader J. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ. Res. 81:1997;154-164.
4. Jabs C.M., Sigurdsson G.H., Neglen P. Plasma levels of high-energy compounds compared with severity of illness in critically ill patients in the intensive care unit. Surgery. 124:1998;65-72.
5. Quinlan G.J., Lamb N.J., Tilley R., Evans T.W., Gutteridge J.M. Plasma hypoxanthine levels in ARDS: implications for oxidative stress, morbidity, and mortality. Am. J. Respir. Crit. Care M. 155:1997;479-484.
6. Rodriguez-Nunez A., Cid E., Rodriguez-Garcia J., Camina F., Rodriguez-Segade S., Castro-Gago M. Concentrations of nucleotides, nucleosides, purine bases, oxypurines, uric acid, and neuron-specific enolase in the cerebrospinal fluid of children with sepsis. J. Child Neurol. 16:2001;704-706.
7. Martin C., Leone M., Viviand X., Ayem M.L., Guieu R. High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. Crit. Care M. 28:2000;3198-3202.
8. Londos C., Cooper D.M., Wolff J. Subclasses of external adenosine receptors. Proc. Natl. Acad. Sci. USA. 77:1980;2551-2554.
9. Witko-Sarsat V., Rieu P., Descamps-Latscha B., Lesavre P., Halbwachs-Mecarelli L. Neutrophils: molecules, functions and pathophysiological aspects. Lab. Invest. 80:2000;617-653.
10. Nathan C., Srimal S., Farber C., Sanchez E., Kabbash L., Asch A., Gailit J., Wright S.D. Cytokine induced respiratory burst of human neutrophils: dependence on extracellular matrix proteins and cd11/cd18 integrins. J. Cell Biol. 109:1989;1341-1349.
11. Arfors K.E., Lundberg C., Lindbom L., Lundberg K., Beatty P.G., Harlan J.M. A monoclonal antibody to the membrane glycoprotein complex CD18 inhibits polymorphonuclear leukocyte accumulation and plasma leakage in vivo. Blood. 69:1987;338-340.
12. Pearson J.D., Gordon J.L. Nucleotide metabolism by endothelium. Ann. Rev. Physiol. 47:1985;617-627.
13. Newby A.C., Holmquist C.A. Adenosine production inside rat polymorphonuclear leukocytes. Biochem. J. 200:1981;399-403.
14. Cronstein B.N., Levin R.I., Belanoff J., Weissman G., Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J. Clin. Invest. 78:1986;760-770.
15. Thiel M., Chambers J.D., Chouker A., Fischer S., Zourelidis C., Bardenheuer H.J., Peter K. Effect of adenosine on the expression of β2-integrins and l-selectin of polymorphonuclear leukocytes in vitro. J. Leukocyte Biol. 59:1996;671-682.
16. Cronstein B.N., Levin R.I., Philips M., Hirschhorn R., Abramson S.B., Weissmann G. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J. Immunol. 148:1992;2201-2206.
17. Cronstein B.N., Rosenstein E.D., Kramer S.B., Weissmann G., Hirschhorn R. Adenosine: a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. J. Immunol. 2:1985;1366-1371.
18. Richter J. Effect of adenosine analogues and cAMP-raising agents on TNF-, GM-CSF-, and chemotactic peptide-induced degranulation in single adherent neutrophils. J. Leukocyte Biol. 51:1992;270-275.
19. Thiel M., Chouker A. Acting via A2 receptors, adenosine inhibits the production of tumor necrosis factor-α of endotoxin-stimulated human polymorphonuclear leukocytes. J. Lab. Clin. M. 124:1995;275-282.
20. Gessi S., Varani K., Merighi S., Cattabriga E., Iannotta V., Leung E., Baraldi P.G., Borea P.A. A(3) adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. Mol. Pharmacol. 61:2002;415-424.
21. 2-generation, respectively. J. Clin. Invest. 85:1990;1150-1157.
22. Sullivan G.W., Linden J., Hewlett E.L., Carper H.T., Hylton J.B., Mandell G.L. Adenosine and related compounds counteract tumor necrosis factor-α inhibition of neutrophil migration: implication of a novel cyclic amp-independent action on the cell surface. J. Immunol. 145:1990;1537-1544.
23. Cronstein B.N., Kramer S.B., Rosenstein E.D., Korchak H.M., Weissmann G., Hirschorn R. Occupancy of adenosine receptors raises cyclic AMP alone and in synergy with occupancy of chemoattractant receptors and inhibits membrane depolarization. Biochem. J. 252:1988;709-715.
24. Gibson-Berry K.L., Whitin J.C., Cohen H.J. Modulation of the respiratory burst in human neutrophils by isoproterenol and dibutyryl cyclic AMP. J. Neuroimmunol. 43:1993;59-68.
25. Talpain E., Armstrong R.A., Coleman R.A., Vardey C.J. Characterization of the PGE receptor subtype mediating inhibition of superoxide production in human neutrophils. Br. J. Pharmacol. 114:1995;1459-1465.
26. 2A receptors promotes fMLP-induced cyclic AMP accumulation in human neutrophils: impact on phospholipase D activity and recruitment of small GTPases to membranes. J. Leukocyte Biol. 71:2002;367-377.
27. Thiel M., Bardenheuer H., Pöch G., Madel C., Peter K. Pentoxifylline does not act via adenosine receptors in the inhibition of the superoxide anion production of human polymorphonuclear leukocytes. Biochem. Biophys. Res. Commun. 180:1991;53-58.
28. 2A) receptor agonists. Br. J. Pharmacol. 132:2001;1017-1026.
29. Ottonello L., Amelotti M., Barbera P., Dapino P., Mancini M., Tortolina G., Dallegri F. Chemoattractant-induced release of elastase by tumor necrosis factor-primed human neutrophils: auto-regulation by endogenous adenosine. Inflamm. Res. 48:1999;637-642.
30. Zalavary S., Bengtsson T. Adenosine inhibits actin dynamics in human neutrophils: evidence for the involvement of cAMP. Eur. J. Cell Biol. 75:1998;128-139.
31. 2A receptors mediate the inhibitory effect of adenosine on formyl-Met-Leu-Phe-stimulated respiratory burst in neutrophil leucocytes. Naunyn Schmiedebergs Arch. Pharmacol. 354:1996;262-267.
32. Cronstein B.N., Haines K.A. Stimulus-response uncoupling in the neutrophil. Adenosine A2-receptor occupancy inhibits the sustained, but not the early, events of stimulus transduction in human neutrophils by a mechanism independent of actin-filament formation. Biochem. J. 281:(Pt 3):1992;631-635.
33. Cronstein B.N., Haines K.A., Kolasinski S., Reibman J. Occupancy of G alpha s-linked receptors uncouples chemoattractant receptors from their stimulus-transduction mechanisms in the neutrophil. Blood. 80:1992;1052-1057.
34. Revan S., Montesinos M.C., Naime D., Landau S., Cronstein B.N. Adenosine A2 receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase. J. Biol. Chem. 271:1996;17114-17118.
35. 2A receptor antagonism. J. Leukocyte Biol. 67:2000;529-535.
36. 2) release by activated human neutrophils. Clin. Immunol. Immunopathol. 42:1987;76-85.
37. Kubersky S.M., Hirschhorn R., Broekman M.J., Cronstein B.N. Occupancy of adenosine receptors on human neutrophils inhibits respiratory burst stimulated by ingestion of complement-coated particles and occupancy of chemoattractant but not Fc receptors. Inflammation. 13:1989;591-599.
38. Zalavary S., Bengtsson T. Modulation of the chemotactic peptide- and immunoglobulin G-triggered respiratory burst in human neutrophils by exogenous and endogenous adenosine. Eur. J. Pharmacol. 354:1998;215-225.
39. Zalavary S., Stendahl O., Bengtsson T. The role of cyclic AMP, calcium and filamentous actin in adenosine modulation of Fc receptor-mediated phagocytosis in human neutrophils. Biochim. Biophys. Acta. 1222:1994;249-256.
40. Lew D.P., Andersson T., Hed J., Pozzan T. Ca-dependent and Ca-independent phagocytosis in human neutrophils. Nature. 315:1985;509-511.
41. Smith R.J., Iden S.S., Bowman B.J. Activation of the human neutrophil respiratory burst with zymosan activated serum. Biochem. Biophys. Res. Commun. 121:1984;695-701.
42. White J.R., Naccache P.H., Molski T.F., Borgeat P. Direct demonstration of increased intracellular concentration of free calcium in rabbit and human neutrophils following stimulation by chemotactic factor. Biochem. Biophys. Res. Commun. 113:1983;44-50.
43. Thiel M., Bardenheuer H. Regulation of oxygen radical production of human polymorphonuclear leukocytes by adenosine: the role of calcium. Pflügers Archiv. 420:1992;522-528.
44. Thiel M., Holzer K., Kreimeier U., Mortiz S., Peter K., Messmer K. Effects of adenosine on the functions of circulating polymorphonuclear leukocytes during hyperdynamic endotoxemia. Infect. Immun. 65:1997;2136-2144.
45. Smail E.H., Cronstein B.N., Meshulam T., Esposito A.L., Ruggeri R.W., Diamond R.D. In vitro, Candida albicans releases the immune modulator adenosine and a second, high-molecular weight agent that blocks neutrophil killing. J. Immunol. 148:1992;3588-3595.
46. Hardart G.E., Sullivan G.W., Carper H.T., Mandell G.L. Adenosine and 2-phenylaminoadenosine (CV-1808) inhibit human neutrophil bactericidal function. Infect. Immun. 59:1991;885-889.
47. Broussas M., Cornillet-Lefebvre P., Potron G., Nguyen P. Inhibition of fMLP-triggered respiratory burst of human monocytes by adenosine: involvement of A3 adenosine receptor. J. Leukocyte Biol. 66:1999;495-501.
48. Sajjadi F.G., Takabayashi K., Foster A.C., Domingo R.C., Firestein G.S. Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J. Immunol. 156:1996;3435-3442.
49. 2A) receptors in human monocytic THP-1 cells. J. Immunol. 167:2001;4026-4032.
50. 2B adenosine receptor expression in macrophages: a mechanism of macrophage deactivation. J. Immunol. 162:1999;3607-3614.
51. 2A receptors inhibits IL-12 production by human monocytes. J. Immunol. 164:2000;436-442.
52. Panther E., Idzko M., Herouy Y., Rheinen H., Gebicke-Haerter P.J., Mrowietz U., Dichmann S., Norgauer J. Expression and function of adenosine receptors in human dendritic cells. FASEB J. 15:2001;1963-1970.
53. Kambayashi T., Wallin R.P., Ljunggren H.G. cAMP-elevating agents suppress dendritic cell function. J. Leukocyte Biol. 70:2001;903-910.
54. 2A extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood. 90:1997;1600-1610.
55. Pastan I.H., Johnson G.S., erson J. Role of cyclic nucleotides in growth control. Annu. Rev. Immunol. 44:1975;491-522. Ref Type: Journal (Full).
56. Bonnafous J.C., Dornand J., Favero J., Mani J.C. Lymphocyte membrane adenosine receptors coupled to adenylate cyclase: properties and occurrence in various lymphocyte subclasses. J. Recept. Res. 2:1981;347-366.
57. Holte H., Torjesen P., Blomhoff H.K., Ruud E., Funderud S., Smeland E.B. Cyclic AMP has the ability to influence multiple events during B cell stimulation. Eur. J. Immunol. 18:1988;1359-1366.
58. Christoffersen J., Smeland E.B., Stokke T., Tasken K., Andersson K.B., Blomhoff H.K. Retinoblastoma protein is rapidly dephosphorylated by elevated cyclic adenosine monophosphate levels in human B-lymphoid cells. Cancer Res. 54:1994;2245-2250.
59. Naderi S., Gutzkow K.B., Christoffersen J., Smeland E.B., Blomhoff H.K. cAMP-mediated growth inhibition of lymphoid cells in G1: rapid down-regulation of cyclin D3 at the level of translation. Eur. J. Immunol. 30:2000;1757-1768.
60. 2A receptor monoclonal antibodies. Mol. Pharmacol. 55:1999;614-624.
61. 2A) receptor independent effects of extracellular adenosine on murine thymocytes in conditions of adenosine deaminase deficiency. Blood. 95:2000;3859-3867.
62. Ohta A., Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 414:2001;916-920.
63. 2A purinergic receptor-mediated signaling in murine T cells. J. Biol. Chem. 272:1997;25881-25889.
64. Boerbooms A.M., Kerstens P.J., van Loenhout J.W., Mulder J., van de Putte L.B. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin. Arthritis Rheum. 24:1995;411-421.
65. Smith J.D., Knox J.M. Psoriasis, methotrexate and tuberculosis. Br. J. Dermatol. 84:1971;590-593.
66. Binymin K., Cooper R.G. Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford). 40:2001;341-342.
67. Chan E.S., Cronstein B.N. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 4:2002;266-273.
68. Valdes L., San Jose E., Alvarez D., Valle J.M. Adenosine deaminase (ADA) isoenzyme analysis in pleural effusions: diagnostic role, and relevance to the origin of increased ADA in tuberculous pleurisy. Eur. Respir. J. 9:1996;747-751.
69. Lee Y.C., Rogers J.T., Rodriguez R.M., Miller K.D., Light R.W. Adenosine deaminase levels in nontuberculous lymphocytic pleural effusions. Chest. 120:2001;356-361.
70. Fenton M.J., Vermeulen M.W. Immunopathology of tuberculosis: roles of macrophages and monocytes. Infect. Immun. 64:1996;683-690.
71. Cohen E.S., Law W.R., Easington C.R., Cruz K.Q., Nardulli B.A., Balk R.A., Parrillo J.E., Hollenberg S.M. Adenosine deaminase inhibition attenuates microvascular dysfunction and improves survival in sepsis. Am. J. Respir. Crit. Care M. 166:2002;16-20.
72. Adanin S., Yalovetskiy I.V., Nardulli B.A., Sam A.D., Jonjev Z.S., Law W.R. Inhibiting adenosine deaminase modulates the systemic inflammatory response syndrome in endotoxemia and sepsis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282:2002;R1324-R1332.
73. Firestein G.S., Boyle D., Bullough D.A., Gruber H.E., Sajjadi F.G., Montag A., Sambol B., Mullane K.M. Protective effect of an adenosine kinase inhibitor in septic shock. J. Immunol. 152:1994;5853-5859.
74. Noji T., Takayama M., Mizutani M., Okamura Y., Takai H., Karasawa A., Kusaka H. KF24345, an adenosine uptake inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor-alpha production and leukopenia via endogenous adenosine in mice. J. Pharmacol. Exp. Ther. 300:2002;200-205.
75. Motew S.J., Mourelatos M.G., Miller R.N., Ferguson J.L., Law W.R. Evidence that adenosine contributes to maintenance of hepatosplanchnic blood flow during peritoneal sepsis in rats. Shock. 7:1997;439-446.
76. Thiel M., Kreimeier U., Holzer K., Moritz S., Peter K., Messmer K. Effects of adenosine on cardiopulmonary functions and oxygen status during hyperdynamic endotoxemia. Crit. Care M. 26:1998;322-337.
77. Parmely M.J., Zhou W.W., Edwards C.K., Borcherding D.R., Silverstein R., Morrison D.C. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J. Immunol. 151:1993;389-396.
78. Hasko G., Szabo C., Nemeth Z.H., Kvetan V., Pastores S.M., Vizi E.S. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J. Immunol. 157:1996;4634-4640.
79. Moochhala S.M., Hon W.M., Chhatwal V.J., Khoo H.E. Expression of inducible nitric oxide synthase in mice: pharmacological evaluation of adenosine receptor agonists. Eur. J. Pharmacol. 316:1996;287-296.
80. 2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram. J. Infect. Dis. 180:1999;1550-1560.
81. Hogan C.J., Fang G.D., Scheld W.M., Linden J., Diduch D.R. Inhibiting the inflammatory response in joint sepsis. Arthroscopy. 17:2001;311-315.
82. Szabo C., Scott G.S., Virag L., Egnaczyk G., Salzman A.L., Shanley T.P., Hasko G. Suppression of macrophage inflammatory protein (MIP)-1 alpha production and collagen-induced arthritis by adenosine receptor agonists. Br. J. Pharmacol. 125:1998;379-387.
83. Smolenski R.T., Kochan Z., McDouall R., Seymour A.M., Yacoub M.H. Adenosine uptake and metabolism in human endothelial cells. Adv. Exp. Med. Biol. 370:1994;435-438.
84. Marton A., Pacher P., Murthy K.G., Nemeth Z.H., Hasko G., Szabo C. Anti-inflammatory effects of inosine in human monocytes, neutrophils and epithelial cells in vitro. Int. J. Mol. M. 8:2001;617-621.
85. Martini C., Trincavelli L., Fiorini M., Salvetti F., Montali U., Falleni A., Gremigni V., Lucacchini A. A1 adenosine receptors in human neutrophils. Electron microscope localization. Adv. Exp. Med. Biol. 431:1998;107-111.
86. Ezeamuzie C.I., Philips E. Adenosine A3 receptors on human eosinophils mediate inhibition of degranulation and superoxide anion release. Br. J. Pharmacol. 127:1999;188-194.
87. Peachell P.T., Lichtenstein L.M., Schleimer R.P. Inhibition by adenosine of histamine and leukotriene release from human basophils. Biochem. Pharmacol. 38:1989;1717-1725.
88. 2B adenosine receptor subtypes. Biochem. Pharmacol. 55:1998;627-633.
89. Marquardt D.L., Walker L.L., Heinemann S. Cloning of two adenosine receptor subtypes from mouse bone marrow-derived mast cells. J. Immunol. 152:1994;4508-4515.
90. Salvatore C.A., Tilley S.L., Latour A.M., Fletcher D.S., Koller B.H., Jacobson M.A. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem. 275:2000;4429-4434.
91. Salmon J.E., Brogle N., Brownlie C., Edberg J.C., Kimberly R.P., Chen B.X., Erlanger B.F. Human mononuclear phagocytes express adenosine A1 receptors. A novel mechanism for differential regulation of Fc gamma receptor function. J. Immunol. 151:1993;2775-2785.
92. 2A) receptor agonists and endotoxin. Am. J. Pathol. 160:2002;2231-2244.
93. Bowlin T.L., Borcherding D.R., Edwards C.K. III, McWhinney C.D. Adenosine A3 receptor agonists inhibit murine macrophage tumor necrosis factor-alpha production in vitro and in vivo. Cell Mol. Biol. (Noisy-le-grand). 43:1997;345-349.
94. 2B adenosine receptors in human lymphocytes: their role in T cell activation. J. Cell Sci. 112:1999;491-502.
95. Hoskin D.W., Butler J.J., Drapeau D., Haeryfar S.M., Blay J. Adenosine acts through an A3 receptor to prevent the induction of murine anti-CD3-activated killer T cells. Int. J. Cancer. 99:2002;386-395.
96. Priebe T., Platsoucas C.D., Nelson J.A. Adenosine receptors and modulation of natural killer cell activity by purine nucleosides. Cancer Res. 50:1990;4328-4331.
97. 2A adenosine receptors in human platelet membranes by [3H]-CGS 21680 binding. Br. J. Pharmacol. 117:1996;1693-1701.
98. 2A receptors increase arterial endothelial cell nitric oxide. J. Surg. Res. 80:1998;357-364.
99. 2B receptors in angiogenic factor regulation. Circ. Res. 90:2002;531-538.